Hypertension Diagnostics, Inc. Newsroom


	Hypertension Diagnostics Announces Warrant Offering ST. PAUL, MN – April 5, 2002 – Hypertension Diagnostics, Inc., (NASDAQ SmallCap: HDII), announced today that it filed a registration statement with the Securities and Exchange Commission in connection with its proposed offering of up to 2,356,073 Redeemable Class B Warrants enabling holders to purchase one share of the Company’s $.01 par value Common Stock (the “Class B Warrants”).
	As an incentive to exercise the Company’s outstanding Redeemable Class A Warrants, the Company is planning to offer the Class B Warrants to those holders of the Redeemable Class A Warrants, issued in connection with the Company’s initial public offering (the “Class A Warrants”), who properly exercise a Class A Warrant after the effective date of the offering and on or before the termination of the offering. The terms of the offering, including the reduction of the respective exercise prices of the Class A Warrants and the Class B Warrants, will be determined upon effectiveness of the offering. A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2001 Annual Report on Form 10-KSB under the caption “Risk Factors,” as well as others not now anticipated. CVProfilor is a registered trademark of Hypertension Diagnostics, Inc. Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved. Investor Relations: Jens Dalsgaard and Tony Altavilla, Managing Directors Redwood Consultants, LLC Mill Valley, CA 94941 415-380-0500 Contact: Greg H. Guettler, President Return to the Main HDI Newsroom Back to Top

Copyright © 2009 Hypertension Diagnostics, Inc Last revised Wednesday February 11, 2009 HDI Legal Information